Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis
| Autor: | Mark Levental, Jean-Louis Stril, Calvin Melmed, Michel Constantin, Hyman M. Schipper, Douglas L. Arnold, Haixiang Su, Francois GrandʼMaison, Fraser Moore, Jean Godin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Adolescent Pilot Projects Pharmacology Acetylcysteine Lesion Young Adult Pharmacotherapy Multiple Sclerosis Relapsing-Remitting Outcome Assessment Health Care medicine Humans Pharmacology (medical) Glatiramer acetate medicine.diagnostic_test business.industry Multiple sclerosis Experimental autoimmune encephalomyelitis Magnetic resonance imaging Free Radical Scavengers Glatiramer Acetate Middle Aged medicine.disease Glutathione Magnetic Resonance Imaging Tolerability Drug Therapy Combination Female Neurology (clinical) medicine.symptom business Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Zdroj: | Clinical neuropharmacology. 38(4) |
| ISSN: | 1537-162X |
| Popis: | Introduction Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system where inflammation and neurodegeneration play key roles. Mounting evidence implicates oxidative stress in the development of irreversible neuronal and glial injury in this condition. N-acetylcysteine (NAC) is a sulfhydryl amino acid derivative with antioxidant and antiapoptotic properties. Administration of NAC to mice attenuated the induction of or improved experimental autoimmune encephalomyelitis (an MS model). Methods We performed an open-label study to explore the tolerability and safety of the combination of glatiramer acetate (GA) and NAC in patients with relapsing-remitting multiple sclerosis at the outpatient MS clinics of the Jewish General Hospital and Hopital Charles Lemoyne, Montreal, Canada. Seven patients with relapsing-remitting multiple sclerosis with at least one T1 gadolinium-enhancing lesion on screening magnetic resonance imaging were recruited. Treatment consisted of a 10-week run-in period followed by 36-week treatment with a combination of GA 20 mg subcutaneously once daily plus NAC 2.5 g orally twice daily. Outcome measures included safety and tolerability, redox biochemistry, and magnetic resonance imaging effect. Results Treatment with the combination of GA and NAC was safe and well tolerated. Conclusions In light of the favorable safety profile, an efficacy-demonstrating study may be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|